$VCEL
Vericel Corp Stock $vcel

$vcel Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-K Financial Statement

#000162828018002753 Filed on March 05, 2018

Income Statement

Concept	2018 Q1	2017 Q4	2017
Revenue	$18.03M	$23.35M	$63.92M
YoY Change	92.58%	0.0%	17.54%
Cost Of Revenue	$7.666M	$8.390M	$30.35M
YoY Change	7.84%	10.54%	7.23%
Gross Profit	$10.36M	$14.96M	$33.57M
YoY Change	360.08%	0.0%	28.74%
Gross Profit Margin	57.47%	64.07%	52.52%
Selling, General & Admin	$10.95M	$10.18M	$35.61M
YoY Change	30.28%	28.37%	30.02%
% of Gross Profit	105.72%	68.04%	106.08%
Research & Development	$3.729M	$3.590M	$12.94M
YoY Change	7.56%	-15.73%	-15.37%
% of Gross Profit	35.99%	24.0%	38.56%
Depreciation & Amortization	$427.0K	$420.0K	$1.612M
YoY Change	4.4%	-16.0%	-14.53%
% of Gross Profit	4.12%	2.81%	4.8%
Operating Expenses	$14.68M	$13.77M	$48.55M
YoY Change	23.65%	13.05%	7.13%
Operating Profit	-$4.322M	$1.191M	-$14.98M
YoY Change	-55.09%	0.0%	-22.14%
Interest Expense	$432.0K	$50.00K	$92.00K
YoY Change	64.89%	-116.13%	513.33%
% of Operating Profit		4.2%
Other Income/Expense, Net	-$3.337M	-$100.0K	-$2.302M
YoY Change	2052.9%		617.13%
Pretax Income	-$7.660M	$290.0K	-$17.29M
YoY Change	-21.68%	-104.68%	-11.65%
Income Tax		$0.00	$0.00
% Of Pretax Income		0.0%
Net Earnings	-$7.659M	$287.0K	-$17.29M
YoY Change	-21.67%	0.0%	-11.65%
Net Earnings / Revenue	-42.49%	1.23%	-27.04%
Basic Earnings Per Share	-$0.21
Diluted Earnings Per Share	-$0.21	$8.269K	-$518.0K
COMMON SHARES
Basic Shares Outstanding	36.10M shares	34.91M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q1	2017 Q4	2017
SHORT-TERM ASSETS
Cash & Short-Term Investments	$29.80M	$26.90M	$26.90M
YoY Change	50.51%	16.96%	16.96%
Cash & Equivalents	$29.80M	$26.86M	$26.90M
Short-Term Investments
Other Short-Term Assets	$1.358M	$1.581M	$1.600M
YoY Change	33.4%	35.82%	33.33%
Inventory	$3.905M	$3.793M	$3.800M
Prepaid Expenses
Receivables	$13.16M	$18.27M	$18.30M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$48.20M	$50.51M	$50.50M
YoY Change	30.45%	12.93%	12.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.207M	$4.071M	$4.100M
YoY Change	15.64%	5.06%	5.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$4.207M	$4.071M	$4.100M
YoY Change	15.64%	5.06%	5.13%
TOTAL ASSETS
Total Short-Term Assets	$48.20M	$50.51M	$50.50M
Total Long-Term Assets	$4.207M	$4.071M	$4.100M
Total Assets	$52.41M	$54.58M	$54.60M
YoY Change	29.12%	12.3%	12.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.768M	$5.552M	$5.600M
YoY Change	-8.95%	-15.04%	-13.85%
Accrued Expenses	$678.0K	$5.573M	$5.600M
YoY Change	12.07%	23.21%	24.44%
Deferred Revenue		$420.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.600M	$400.0K	$400.0K
YoY Change	14.29%	-50.0%	-50.0%
Total Short-Term Liabilities	$13.88M	$13.09M	$13.10M
YoY Change	-5.92%	1.84%	1.55%
LONG-TERM LIABILITIES
Long-Term Debt	$15.65M	$16.89M	$16.90M
YoY Change	80.31%	81.24%	79.79%
Other Long-Term Liabilities	$1.900M	$2.100M	$2.100M
YoY Change	8947.62%	6462.5%	23.53%
Total Long-Term Liabilities	$15.65M	$2.059M	$19.00M
YoY Change	79.87%	22.05%	71.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.88M	$13.09M	$13.10M
Total Long-Term Liabilities	$15.65M	$2.059M	$19.00M
Total Liabilities	$31.47M	$32.04M	$32.00M
YoY Change	25.47%	34.1%	33.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$368.5M	-$360.9M
YoY Change	4.29%	5.03%
Common Stock	$389.1M	$383.0M
YoY Change	5.53%	16.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$20.94M	$22.54M	$22.50M
YoY Change
Total Liabilities & Shareholders Equity	$52.41M	$54.58M	$54.60M
YoY Change	29.12%	12.3%	12.35%

Cashflow Statement

Concept	2018 Q1	2017 Q4	2017
OPERATING ACTIVITIES
Net Income	-$7.659M	$287.0K	-$17.29M
YoY Change	-21.67%	0.0%	-11.65%
Depreciation, Depletion And Amortization	$427.0K	$420.0K	$1.612M
YoY Change	4.4%	-16.0%	-14.53%
Cash From Operating Activities	$405.0K	$840.0K	-$13.18M
YoY Change	-112.97%	-109.02%	-33.73%
INVESTING ACTIVITIES
Capital Expenditures	$184.0K	-$720.0K	$1.510M
YoY Change	-362.86%	554.55%	6.71%
Acquisitions	$0.00
YoY Change	-100.0%
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$184.0K	-$720.0K	-$1.510M
YoY Change	162.86%	554.55%	6.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.694M	11.28M	$18.58M
YoY Change	4316.39%	-52.0%	-37.46%
NET CHANGE
Cash From Operating Activities	$405.0K	840.0K	-$13.18M
Cash From Investing Activities	-$184.0K	-720.0K	-$1.510M
Cash From Financing Activities	$2.694M	11.28M	$18.58M
Net Change In Cash	$2.915M	11.40M	$3.884M
YoY Change	-193.1%	-19.03%	-53.75%
FREE CASH FLOW
Cash From Operating Activities	$405.0K	$840.0K	-$13.18M
Capital Expenditures	$184.0K	-$720.0K	$1.510M
Free Cash Flow	$221.0K	$1.560M	-$14.69M
YoY Change	-107.24%	-116.96%	-31.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q4	astm	Accrued Expenses Other Current AccruedExpensesOtherCurrent	422000	USD
CY2017Q4	astm	Accrued Expenses Other Current AccruedExpensesOtherCurrent	491000	USD
CY2011Q3	astm	Class Of Warrant Or Right Additional Number Of Rights Distributed Per Common Share ClassOfWarrantOrRightAdditionalNumberOfRightsDistributedPerCommonShare	1	right
CY2013Q4	astm	Class Of Warrant Or Right Number Of Rights Deemed To Be Delivered Per Common Stock Share Issued Or Transferred ClassOfWarrantOrRightNumberOfRightsDeemedToBeDeliveredPerCommonStockShareIssuedOrTransferred	20	right
CY2011Q3	astm	Class Of Warrant Or Right Number Of Rights Per Common Stock Share ClassOfWarrantOrRightNumberOfRightsPerCommonStockShare	1	right
CY2013Q4	astm	Class Of Warrant Or Right Number Of Rights Per Common Stock Share ClassOfWarrantOrRightNumberOfRightsPerCommonStockShare	20	right
CY2016Q4	astm	Deferred Tax Assets Research And Development Costs DeferredTaxAssetsResearchAndDevelopmentCosts	13659000	USD
CY2017Q4	astm	Deferred Tax Assets Research And Development Costs DeferredTaxAssetsResearchAndDevelopmentCosts	8275000	USD
CY2015	astm	Income Tax Reconciliation Warrants IncomeTaxReconciliationWarrants	-118000	USD
CY2016	astm	Income Tax Reconciliation Warrants IncomeTaxReconciliationWarrants	0	USD
CY2017	astm	Income Tax Reconciliation Warrants IncomeTaxReconciliationWarrants	0	USD
CY2016Q4	astm	Lineof Creditand Term Loan Credit Agreement Current Netof Deferred Costs LineofCreditandTermLoanCreditAgreementCurrentNetofDeferredCosts	779000	USD
CY2017Q4	astm	Lineof Creditand Term Loan Credit Agreement Current Netof Deferred Costs LineofCreditandTermLoanCreditAgreementCurrentNetofDeferredCosts	350000	USD
CY2016Q4	astm	Lineof Creditand Term Loan Credit Agreement Noncurrent Netof Deferred Costs LineofCreditandTermLoanCreditAgreementNoncurrentNetofDeferredCosts	9318000	USD
CY2017Q4	astm	Lineof Creditand Term Loan Credit Agreement Noncurrent Netof Deferred Costs LineofCreditandTermLoanCreditAgreementNoncurrentNetofDeferredCosts	16888000	USD
CY2014Q3	astm	Operating Loss Carryforwards Limitations On Use Projected Annual Limitation On Use Of Net Operating Losses OperatingLossCarryforwardsLimitationsOnUseProjectedAnnualLimitationOnUseOfNetOperatingLosses	800000	USD
CY2017Q4	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDue	22483000	USD
CY2017Q4	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due Current OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueCurrent	5671000	USD
CY2017Q4	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due In Four Years OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueInFourYears	5138000	USD
CY2017Q4	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due In Three Years OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueInThreeYears	5155000	USD
CY2017Q4	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due In Two Years OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueInTwoYears	5178000	USD
CY2017Q4	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due Thereafter OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueThereafter	0	USD
CY2017Q4	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Duein Five Years OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueinFiveYears	1341000	USD
CY2015Q4	astm	Purchase Obligation Automatic Renewal Term PurchaseObligationAutomaticRenewalTerm	P5Y
CY2015Q4	astm	Purchase Obligation Renewal Option Term PurchaseObligationRenewalOptionTerm	P5Y
CY2017	astm	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	4010000	USD
CY2017Q4	astm	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Income Tax Expense TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense	11700000	USD
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
CY2017	dei	Document Type DocumentType	10-K
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0000887359
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36103211	shares
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q2	dei	Entity Public Float EntityPublicFloat	107971565	USD
CY2017	dei	Entity Registrant Name EntityRegistrantName	Vericel Corp
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6535000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5552000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17093000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18270000	USD
CY2016Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	2433000	USD
CY2017Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	2693000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4523000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5573000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7093000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6621000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	190000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	397000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2747000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2499000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2680000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1653000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	311000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	190000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	207000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	225000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	249000	USD
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6700000	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5300000	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5400000	shares
CY2015	us-gaap	Asset Retirement Obligation Liabilities Settled AssetRetirementObligationLiabilitiesSettled	-268000	USD
CY2016	us-gaap	Asset Retirement Obligation Liabilities Settled AssetRetirementObligationLiabilitiesSettled	0	USD
CY2017	us-gaap	Asset Retirement Obligation Liabilities Settled AssetRetirementObligationLiabilitiesSettled	0	USD
CY2016Q4	us-gaap	Assets Assets	48598000	USD
CY2017Q4	us-gaap	Assets Assets	54577000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	44723000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	50506000	USD
CY2015	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	42000	USD
CY2016	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	18000	USD
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	341000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	92000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	80000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	2000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	2000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	2000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	6000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2014Q4	us-gaap	Cash Cash	30343000	USD
CY2015Q4	us-gaap	Cash Cash	14581000	USD
CY2016Q4	us-gaap	Cash Cash	22978000	USD
CY2017Q4	us-gaap	Cash Cash	26862000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31595000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35861000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31595000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35861000	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	329720000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	383020000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16269000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19566000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17286000	USD
CY2017Q1	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	0	shares
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	26470000	USD
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	28307000	USD
CY2017	us-gaap	Cost Of Goods Sold CostOfGoodsSold	30354000	USD
CY2016Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	110000	USD
CY2017Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	67000	USD
CY2016Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	293000	USD
CY2017Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	196000	USD
CY2017Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	1700000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	3000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	420000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	29692000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	24248000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	1898000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	2568000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10343000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10487000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	196000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	282000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	700000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	508000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2896000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2128000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29692000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	24248000	USD
CY2015	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	500000	USD
CY2016	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	600000	USD
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	600000	USD
CY2015	us-gaap	Depreciation Depreciation	1300000	USD
CY2016	us-gaap	Depreciation Depreciation	1600000	USD
CY2017	us-gaap	Depreciation Depreciation	1600000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1592000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1886000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1612000	USD
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.97
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.18
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.01
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1668000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2389000	USD
CY2015	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-324000	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	257000	USD
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-67000	USD
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-5000	USD
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-37000	USD
CY2015	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	35000	USD
CY2016	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2017	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	115000	USD
CY2015	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-860000	USD
CY2015	us-gaap	Gross Profit GrossProfit	24698000	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	7548000	USD
CY2016Q2	us-gaap	Gross Profit GrossProfit	5523000	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	4073000	USD
CY2016Q4	us-gaap	Gross Profit GrossProfit	8932000	USD
CY2016	us-gaap	Gross Profit GrossProfit	26076000	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	2252000	USD
CY2017Q2	us-gaap	Gross Profit GrossProfit	9283000	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	7074000	USD
CY2017Q4	us-gaap	Gross Profit GrossProfit	14961000	USD
CY2017	us-gaap	Gross Profit GrossProfit	33570000	USD
CY2015	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2016	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2638000	USD
CY2017	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2016Q1	us-gaap	Incentive From Lessor IncentiveFromLessor	2000000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16340000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-19566000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-17286000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	10669000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7677000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-5445000	USD
CY2015	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-614000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	11749000	USD
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5556000	USD
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6652000	USD
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5877000	USD
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	543000	USD
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	549000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	563000	USD
CY2015	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	57000	USD
CY2016	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	56000	USD
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	116000	USD
CY2015	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-392000	USD
CY2016	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1016000	USD
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1106000	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	100000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1726000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1076000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1361000	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-764000	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	920000	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1050000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	86000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2245000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	657000	USD
CY2015	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-572000	USD
CY2016	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	701000	USD
CY2017	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	261000	USD
CY2015	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-132000	USD
CY2016	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	217000	USD
CY2017	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	41000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	0	USD
CY2016	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-898000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-798000	USD
CY2015	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	2728000	USD
CY2016	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	6174000	USD
CY2017	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1177000	USD
CY2015	us-gaap	Interest Expense InterestExpense	9000	USD
CY2016	us-gaap	Interest Expense InterestExpense	314000	USD
CY2017	us-gaap	Interest Expense InterestExpense	1107000	USD
CY2015	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	226000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	931000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	17000	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	35000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	3488000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	3793000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3214000	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3532000	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	257000	USD
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	226000	USD
CY2015	us-gaap	Inventory Write Down InventoryWriteDown	627000	USD
CY2016	us-gaap	Inventory Write Down InventoryWriteDown	137000	USD
CY2017	us-gaap	Inventory Write Down InventoryWriteDown	352000	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	36000	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	14000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	23890000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	32037000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48598000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54577000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12853000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13090000	USD
CY2016Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1687000	USD
CY2017Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2059000	USD
CY2015	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-15762000	USD
CY2016	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	8397000	USD
CY2017	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	3884000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-24000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29704000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18577000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2392000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1415000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1510000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13346000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19892000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13183000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-16340000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-3650000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-3044000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-6675000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-6197000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-19566000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-9778000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-2388000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-5407000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	287000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-17286000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23076000	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27145000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17286000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	331000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-321000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2302000	USD
CY2017	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2015	us-gaap	Operating Expenses OperatingExpenses	41369000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	45321000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	48554000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-16671000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1992000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4984000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6380000	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-5889000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-19245000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9623000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2521000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4031000	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	1191000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-14984000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	19336000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	4878000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	761000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	4558000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	4575000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4564000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4900000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4800000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	5600000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1164000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1581000	USD
CY2015	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	71000	USD
CY2016	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2017	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	256000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	181000	USD
CY2016Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	32000	USD
CY2017Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	0	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-20000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-15000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-92000	USD
CY2015	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2016	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2017	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	1164000	USD
CY2015	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-35000	USD
CY2016	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
CY2017	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
CY2015	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2016	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2017	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	583000	USD
CY2015	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2016	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	213000	USD
CY2017	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	30000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2427000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1415000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1510000	USD
CY2015	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6736000	USD
CY2016	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	7579000	USD
CY2017	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	190000	USD
CY2017	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	207000	USD
CY2015	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	11000	USD
CY2016	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	19455000	USD
CY2017	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	8220000	USD
CY2015	us-gaap	Proceeds From Secured Lines Of Credit ProceedsFromSecuredLinesOfCredit	0	USD
CY2016	us-gaap	Proceeds From Secured Lines Of Credit ProceedsFromSecuredLinesOfCredit	12710000	USD
CY2017	us-gaap	Proceeds From Secured Lines Of Credit ProceedsFromSecuredLinesOfCredit	14793000	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4010000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10968000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10692000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3875000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4071000	USD
CY2017Q4	us-gaap	Purchase Obligation PurchaseObligation	3055000	USD
CY2017Q4	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2017Q4	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	578000	USD
CY2017Q4	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	578000	USD
CY2017Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	713000	USD
CY2017Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	608000	USD
CY2015Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	600000	USD
CY2017Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	578000	USD
CY2015	us-gaap	Repayments Of Debt RepaymentsOfDebt	35000	USD
CY2016	us-gaap	Repayments Of Debt RepaymentsOfDebt	38000	USD
CY2017	us-gaap	Repayments Of Debt RepaymentsOfDebt	7151000	USD
CY2015	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2016	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	2400000	USD
CY2017	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	889000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18890000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15295000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12944000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-343591000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-360877000	USD
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	51168000	USD
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	54383000	USD
CY2017	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	62760000	USD
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	51168000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	14108000	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	12823000	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	10929000	USD
CY2016Q4	us-gaap	Sales Revenue Net SalesRevenueNet	16523000	USD
CY2016	us-gaap	Sales Revenue Net SalesRevenueNet	54383000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	9361000	USD
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	16953000	USD
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	14260000	USD
CY2017Q4	us-gaap	Sales Revenue Net SalesRevenueNet	23350000	USD
CY2017	us-gaap	Sales Revenue Net SalesRevenueNet	63924000	USD
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22479000	USD
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27388000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	35610000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	2747000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	2499000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	2680000	USD
CY2015	us-gaap	Stock Issued1 StockIssued1	3150000	USD
CY2016	us-gaap	Stock Issued1 StockIssued1	-3150000	USD
CY2017	us-gaap	Stock Issued1 StockIssued1	-38389000	USD
CY2016	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2016	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	467000	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	425000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	18868000	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7188000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	120000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	608000	USD
CY2015	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	0	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	35641000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	22130000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	24708000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	22540000	USD
CY2015	us-gaap	Straight Line Rent StraightLineRent	0	USD
CY2016	us-gaap	Straight Line Rent StraightLineRent	-670000	USD
CY2017	us-gaap	Straight Line Rent StraightLineRent	13000	USD
CY2015	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	-5203000	USD
CY2016	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	0	USD
CY2017	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	0	USD
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7700000	USD
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-5400000	USD
CY2016Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	757000	USD
CY2017Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1014000	USD
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23760000	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23093000	shares
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33355000	shares
CY2017	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vericel Corporation, a Michigan corporation (the Company, Vericel, we, us or our), was incorporated in March 1989 and began employee-based operations in 1991. On May 30, 2014, Vericel completed the acquisition of certain assets and assumed certain liabilities of Sanofi, a French </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">société anonyme</font><font style="font-family:inherit;font-size:10pt;"> (Sanofi), including all of the outstanding equity interests of Genzyme Biosurgery ApS (Genzyme Denmark or the Danish subsidiary) (now known as Vericel Denmark ApS), a wholly-owned subsidiary of Sanofi, and a portfolio of patents and patent applications of Sanofi and certain of its subsidiaries for purposes of acquiring the portion of the cell therapy and regenerative medicine business (the CTRM Business), which researches, develops, manufactures, markets and sells the MACI</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> and Epicel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> products. The Company is a fully integrated, commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of innovative therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. Vericel has marketed products and developmental stage product candidates, and the Company’s goal is to become the leader in cell therapy and regenerative medicine by developing, manufacturing and marketing best-in-class therapies for patients with significant unmet medical needs. </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates its business primarily in the U.S. in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> reportable segment — the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies to repair and regenerate damaged tissues and organs to normal structure and function.</font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#222222;">The accompanying consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business.  As of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;color:#222222;">, the Company has an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$360.9 million</font><font style="font-family:inherit;font-size:10pt;color:#222222;"> and had a net loss of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$17.3 million</font><font style="font-family:inherit;font-size:10pt;color:#222222;"> during 2017.  The Company had cash of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$26.9 million</font><font style="font-family:inherit;font-size:10pt;color:#222222;"> as of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;color:#222222;">. The Company expects that existing cash together with its </font><font style="font-family:inherit;font-size:10pt;">term loan and revolving line of credit agreement with Silicon Valley Bank (SVB) and MidCap Financial Services (MidCap) (the</font><font style="font-family:inherit;font-size:10pt;color:#222222;"> SVB-MidCap facility), will be sufficient to support the Company's </font><font style="font-family:inherit;font-size:10pt;">current operations through at least March 31, 2019</font><font style="font-family:inherit;font-size:10pt;color:#222222;">.  In connection with the SVB-MidCap facility, </font><font style="font-family:inherit;font-size:10pt;">the Company must remain in compliance with minimum monthly net revenue covenants (determined in accordance with U.S. GAAP), measured on a trailing twelve month basis. The December 31, 2018 minimum revenue covenant is set at </font><font style="font-family:inherit;font-size:10pt;">$63.6 million</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;color:#222222;">SVB and MidCap also have the ability to call debt based on material adverse change clauses which are subjectively determinable and result in a </font><font style="font-family:inherit;font-size:10pt;">subjective acceleration clause. </font><font style="font-family:inherit;font-size:10pt;color:#222222;">If the Company's cash requirements exceed its current expectations, or if it is not in compliance with the monthly net revenue covenants or the subjective acceleration clauses are triggered under the SVB-MidCap Facility, then SVB may call the debt resulting in the Company immediately needing additional funds. As of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;color:#222222;">, the Company was in compliance with the minimum revenue covenant set forth in the Third Loan Modification Agreement between the Company, SVB and MidCap. The Company may seek additional funding through debt or equity financings including the at-the-market sales agreement in place with </font><font style="font-family:inherit;font-size:10pt;">Cowen and Company, LLC</font><font style="font-family:inherit;font-size:10pt;color:#222222;">.  However, the Company may not be able to obtain financing on acceptable terms or at all. The terms of any financing may adversely affect the holdings or the rights of the Company's shareholders.  If the Company needs additional funds and is unable to obtain funding on a timely basis, the Company may need to significantly curtail its operations in an effort to provide sufficient funds to continue its operations, which could adversely affect its business prospects.</font></div></div>
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reported period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-18-002753-index-headers.html	Edgar Link	pending
0001628280-18-002753-index.html	Edgar Link	pending
0001628280-18-002753.txt	Edgar Link	pending
0001628280-18-002753-xbrl.zip	Edgar Link	pending
astm-20161231.xml	Edgar Link	completed
astm-20161231.xsd	Edgar Link	pending
astm-20161231_cal.xml	Edgar Link	unprocessable
astm-20161231_def.xml	Edgar Link	unprocessable
astm-20161231_lab.xml	Edgar Link	unprocessable
astm-20161231_pre.xml	Edgar Link	unprocessable
ex1056secondamendmenttothe.htm	Edgar Link	pending
ex1057thirdamendmenttodist.htm	Edgar Link	pending
ex1058amendedandrestatedno.htm	Edgar Link	pending
ex211subsidiariesofregistr.htm	Edgar Link	pending
ex231consentofregisteredin.htm	Edgar Link	pending
ex311certification.htm	Edgar Link	pending
ex312certification.htm	Edgar Link	pending
ex321certification.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stockchart2017a01.jpg	Edgar Link	pending
vcel12-31x201710k.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VCEL
Vericel Corp Stock $vcel

2018 Q1 Form 10-K Financial Statement

#000162828018002753 Filed on March 05, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL Vericel Corp Stock $vcel

2018 Q1 Form 10-K Financial Statement

#000162828018002753 Filed on March 05, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL
Vericel Corp Stock $vcel